Literature DB >> 15287092

Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.

Sharmila Shankar1, Thiyam Ramsing Singh, Rakesh K Srivastava.   

Abstract

BACKGROUND: We assessed the influence of sequential treatment of ionizing radiation followed by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on intracellular mechanisms of apoptosis of prostate tumor cells in vitro and in vivo.
METHODS: Prostate normal and cancer cells were exposed to irradiation and TRAIL. Four- to 6-week-old athymic nude mice were injected s.c. with PC-3 tumor cells. Tumor bearing mice were exposed to irradiation and TRAIL, either alone or in combination (TRAIL after 24 hr of irradiation), and tumor growth, apoptosis, and survival of mice were examined. Expressions of death receptors, Bcl-2 family members, and caspase were measured by Western blotting, ELISA, and ribonuclease protection assay; tumor cellularity was assessed by H&E staining; inhibition of p53 was performed by RNA interference (RNAi) technology, and apoptosis was measured by annexin V/propidium iodide staining, and terminal deoxynucleotidyltransferase-mediated nick end labeling assay.
RESULTS: Irradiation significantly augmented TRAIL-induced apoptosis in prostate cancer cells through upregulation of DR5, Bax, and Bak, and induction of caspase activation. Dominant negative FADD and p53 siRNA inhibited the synergistic interaction between irradiation and TRAIL. The pretreatment of cells with irradiation followed by TRAIL significantly enhanced more apoptosis than single agent alone or concurrent treatment. Furthermore, irradiation sensitized TRAIL-resistant LNCaP cells to undergo apoptosis. The sequential treatment of xenografted mice with irradiation followed by TRAIL-induced apoptosis through activation of caspase-3, induction of Bax and Bak, and inhibition of Bcl-2, and completely eradicated the established tumors with enhanced survival of nude mice.
CONCLUSION: The sequential treatment with irradiation followed by TRAIL can be used as a viable option to enhance the therapeutic potential of TRAIL in prostate cancer. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15287092     DOI: 10.1002/pros.20069

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  35 in total

1.  PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.

Authors:  Kaiyu Yuan; Yong Sun; Tong Zhou; Jay McDonald; Yabing Chen
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

Review 2.  TRAIL-mediated signaling in prostate, bladder and renal cancer.

Authors:  Christina Voelkel-Johnson
Journal:  Nat Rev Urol       Date:  2011-06-14       Impact factor: 14.432

3.  Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors.

Authors:  Irina V Balyasnikova; Melanie S Prasol; Sherise D Ferguson; Yu Han; Atique U Ahmed; Margarita Gutova; Alex L Tobias; Devkumar Mustafi; Esther Rincón; Lingjiao Zhang; Karen S Aboody; Maciej S Lesniak
Journal:  Mol Ther       Date:  2013-09-03       Impact factor: 11.454

Review 4.  Combined modality therapy with TRAIL or agonistic death receptor antibodies.

Authors:  Hope M Amm; Patsy G Oliver; Choo Hyung Lee; Yufeng Li; Donald J Buchsbaum
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

Review 5.  TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

Authors:  Peter A Holoch; Thomas S Griffith
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

6.  Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells.

Authors:  Ewelina Szliszka; Zenon P Czuba; Bogdan Mazur; Lukasz Sedek; Andrzej Paradysz; Wojciech Krol
Journal:  Int J Mol Sci       Date:  2009-12-24       Impact factor: 5.923

7.  Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.

Authors:  Ji-Young Jang; Yoon-Kyung Jeon; Yun Choi; Chul-Woo Kim
Journal:  Mol Cancer       Date:  2010-09-28       Impact factor: 27.401

8.  Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions.

Authors:  Patrizia Marini; Dorothea Junginger; Stefan Stickl; Wilfried Budach; Maximilian Niyazi; Claus Belka
Journal:  Radiat Oncol       Date:  2009-10-27       Impact factor: 3.481

Review 9.  To kill a tumor cell: the potential of proapoptotic receptor agonists.

Authors:  Avi Ashkenazi; Roy S Herbst
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

10.  Antitumor activity of Ad-IU2, a prostate-specific replication-competent adenovirus encoding the apoptosis inducer, TRAIL.

Authors:  J A Jiménez; X Li; Y-P Zhang; K H Bae; Y Mohammadi; P Pandya; C Kao; T A Gardner
Journal:  Cancer Gene Ther       Date:  2009-10-02       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.